Clinical Trial

A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms

Name: A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms — clinical trial record (NCT07234045)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

A Clinical Study to Explore the Safety, Efficacy and Cellular Metabolic Kinetics of CT1195E CAR-T Cells Injection in Patients with Relapsed/Refractory B-Cell Neoplasms

Trial Details

NCT Number	NCT07234045
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Relapsed/Refractory B-cell ALL
Enrollment	30 participants
Start Date	2025-11-30
Primary Completion	2027-12-30 (estimated)
Study Completion	2028-06-30 (estimated)
Updated on ClinicalTrials.gov	2025-11-18